国际标准期刊号: 2157-2526

生物恐怖主义和生物防御杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 研究圣经
  • 中国知网(CNKI)
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Vaccine Development for Biothreat Alphaviruses

Kevin B Spurgers and Pamela J Glass

The majority of alphaviruses are non-pathogenic to humans. However, select alphaviruses can cause severe disease in humans during the course of naturally occurring epizootic outbreaks, or accidental infection of laboratory personnel. Natural infections occur through the bite of an infected mosquito. However, pathogenic alphaviruses, including Venezuelan, eastern, and western equine encephalitis viruses, have proven to be highly infectious via the aerosol route. Given this aerosol infectivity, ease of production of high-titer virus, and low infectious dose, these alphaviruses are recognized as candidates for use as biological weapons, and are classified as category B pathogens by the Centers for Disease Control and Prevention and The National Institutes of Health. There are currently no licensed vaccines to prevent alphavirus infections. Such a vaccine could protect geographically defined human populations during an epizootic, and enhance national security by serving as a deterrent to the use of these viruses as biological weapons. To address this critical need, several strategies are being pursued to develop safe, effective, and ultimately licensed vaccines for use in humans.